HCDP Manchester

AML MRD Assessment for patients on lower intensity regimens (e.g. venetoclax and azacitidine)

TimepointNPM1 mutated patients Bone marrow NPM1 qPCRAll other patients Bone marrow multiparametric flow cytometry (MFC-MRD)
Post cycle 1YESYES
Post cycle 2YESYES
Post cycle 4YESYES
Post cycle 7YESYES
Home